Establishing Gold Standard Donor Screening Strategies & Determining
Best-In-Class Cell Source Starting Material to Drive Scalability & Spearhead Successful Clinical Outcomes
Welcome to the Donor Selection & Cell Source Summit
As the allogeneic cell therapy space continues to mature with over 150+ clinical trials currently underway, and landmark milestones achieved with the first FDA approvals for allogeneic cell products – all eyes are turning to the backbones of these cell therapies – the cell donors. The field is awakening to the challenging reality of the increased demand for donor material to meet the required dosing needs for later stage clinical trials and licensed products.
Enter the timely arrival of the inaugural Donor Selection and Cell Source Summit, the pioneering forum for cell therapy leaders within process development, supply chain, procurement, R&D and analytics, placing a spotlight focus on cell source starting material for the first time.
Join experts showcasing in-depth case studies of novel technology platforms and cell sources being utilized to increase yield, and new donor characteristic screening strategies to select for ‘gold-standard’ donors to achieve optimal clinical results for patients.
Get caught up to speed on this dynamic space with expertise shared from the likes of Allogene, Caribou Bio, Poseida Therapeutics, and many others as the titans of industry unite to help you advance your knowledge on donor selection, management and sustainability to ensure a consistent and reliable supply of cell source material required for clinical trials and beyond.
What's in Store?
Explore the concept of a ‘super-donor’ to take a deep dive into the critical components and criteria for development of the ultimate donor pool with Artiva Therapeutics and Deverra Therapeutics
Uncover novel strategies for donor screening and characterization testing to benchmark recruitment of best-in-class donors with Allogene, National Children’s Hospital, and Senti Biosciences
Overcome logistical and operational challenges of coordinating with donor sites as Poseida Therapeutics and Caribou to unveil the route to a smooth donor supply chain
Gain insight into the advantages of utilizing different cell sources as a starting material, as ImmuneBridge and HebeCell delve into the use of iPSCs vs PMBC vs cord-blood derived.
World-Class Speaker Faculty Includes:
Amanda Conerty
Executive Director - Process, Analytical Development & Manufacturing
Artiva Biotherapeutics
Colleen Delaney
Scientific Founder, Chief Scientific Officer and Executive VP of R&D
Deverra Therapeutics
This Year's Presenting Companies Include:
Proud to Partner With:
